Holly Ponichtera Email

Director, In Vivo Pharmacology . Evelo Biosciences

Current Roles

Employees:
45
Revenue:
$27M
About
Evelo Biosciences, Inc. is a clinical stage biotechnology company developing oral biologics that act on cells in the small intestine with systemic therapeutic effects. These cells in the small intestine play a central role in governing the immune, metabolic and neurological systems. The company?s first product candidates are monoclonal microbials, single strains of microbes selected for defined pharmacological properties. They have been observed in preclinical models to have systemic dose-dependent effects, modulating multiple clinically validated pathways. Evelo?s therapies have the potential to be effective, safe and affordable medicines to improve the lives of people with chronic disease and cancer. Evelo currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas.
Evelo Biosciences Address
620 Memorial Drive
Cambridge, MA
United States

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.